BioMarin Pharmaceutical (BMRN) Competitors $54.13 +3.93 (+7.82%) As of 02:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRN vs. ALNY, BIIB, UTHR, INCY, and NBIXShould you buy BioMarin Pharmaceutical stock or one of its competitors? MarketBeat compares BioMarin Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. BMRN vs. ALNYBMRN vs. BIIBBMRN vs. UTHRBMRN vs. INCYBMRN vs. NBIXHow does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Is BMRN or ALNY more profitable? Alnylam Pharmaceuticals has a net margin of 11.72% compared to BioMarin Pharmaceutical's net margin of 8.29%. Alnylam Pharmaceuticals' return on equity of 85.76% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical8.29% 6.50% 5.07% Alnylam Pharmaceuticals 11.72%85.76%10.32% Which has stronger valuation and earnings, BMRN or ALNY? BioMarin Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$3.22B3.25$348.90M$1.3739.51Alnylam Pharmaceuticals$3.71B10.80$313.75M$3.6682.07 Do insiders & institutionals have more ownership in BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Do analysts prefer BMRN or ALNY? BioMarin Pharmaceutical currently has a consensus target price of $88.88, suggesting a potential upside of 64.20%. Alnylam Pharmaceuticals has a consensus target price of $463.13, suggesting a potential upside of 54.18%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75Alnylam Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.85 Does the media refer more to BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 16 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 1.03 beat BioMarin Pharmaceutical's score of 0.13 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryAlnylam Pharmaceuticals beats BioMarin Pharmaceutical on 13 of the 16 factors compared between the two stocks.How does BioMarin Pharmaceutical compare to Biogen?Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Which has higher valuation & earnings, BIIB or BMRN? Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.89B2.83$1.29B$9.3220.33BioMarin Pharmaceutical$3.22B3.25$348.90M$1.3739.51 Do analysts recommend BIIB or BMRN? Biogen presently has a consensus target price of $215.62, indicating a potential upside of 13.78%. BioMarin Pharmaceutical has a consensus target price of $88.88, indicating a potential upside of 64.20%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 1 Sell rating(s) 13 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.52BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75 Is BIIB or BMRN more profitable? Biogen has a net margin of 13.81% compared to BioMarin Pharmaceutical's net margin of 8.29%. Biogen's return on equity of 12.83% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Biogen13.81% 12.83% 8.01% BioMarin Pharmaceutical 8.29%6.50%5.07% Which has more risk and volatility, BIIB or BMRN? Biogen has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Do insiders and institutionals believe in BIIB or BMRN? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer BIIB or BMRN? In the previous week, Biogen had 15 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 31 mentions for Biogen and 16 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.78 beat BioMarin Pharmaceutical's score of 0.13 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 9 Very Positive mention(s) 10 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioMarin Pharmaceutical beats Biogen on 9 of the 17 factors compared between the two stocks.How does BioMarin Pharmaceutical compare to United Therapeutics?United Therapeutics (NASDAQ:UTHR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Which has stronger valuation & earnings, UTHR or BMRN? United Therapeutics has higher earnings, but lower revenue than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$3.18B7.53$1.33B$27.0920.85BioMarin Pharmaceutical$3.22B3.25$348.90M$1.3739.51 Which has more volatility and risk, UTHR or BMRN? United Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Do analysts rate UTHR or BMRN? United Therapeutics currently has a consensus target price of $619.42, indicating a potential upside of 9.66%. BioMarin Pharmaceutical has a consensus target price of $88.88, indicating a potential upside of 64.20%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75 Does the media refer more to UTHR or BMRN? In the previous week, United Therapeutics had 16 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 32 mentions for United Therapeutics and 16 mentions for BioMarin Pharmaceutical. United Therapeutics' average media sentiment score of 0.16 beat BioMarin Pharmaceutical's score of 0.13 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioMarin Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of UTHR or BMRN? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is UTHR or BMRN more profitable? United Therapeutics has a net margin of 40.62% compared to BioMarin Pharmaceutical's net margin of 8.29%. United Therapeutics' return on equity of 19.24% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.62% 19.24% 17.25% BioMarin Pharmaceutical 8.29%6.50%5.07% SummaryUnited Therapeutics beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.How does BioMarin Pharmaceutical compare to Incyte?BioMarin Pharmaceutical (NASDAQ:BMRN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Do analysts rate BMRN or INCY? BioMarin Pharmaceutical presently has a consensus price target of $88.88, indicating a potential upside of 64.20%. Incyte has a consensus price target of $104.26, indicating a potential upside of 6.74%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75Incyte 1 Sell rating(s) 10 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has preferable valuation and earnings, BMRN or INCY? Incyte has higher revenue and earnings than BioMarin Pharmaceutical. Incyte is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$3.22B3.25$348.90M$1.3739.51Incyte$5.14B3.80$1.29B$7.0813.80 Does the media favor BMRN or INCY? In the previous week, BioMarin Pharmaceutical had 4 more articles in the media than Incyte. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 12 mentions for Incyte. Incyte's average media sentiment score of 0.81 beat BioMarin Pharmaceutical's score of 0.13 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Incyte 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in BMRN or INCY? 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is BMRN or INCY more profitable? Incyte has a net margin of 26.71% compared to BioMarin Pharmaceutical's net margin of 8.29%. Incyte's return on equity of 26.66% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical8.29% 6.50% 5.07% Incyte 26.71%26.66%19.77% Which has more risk & volatility, BMRN or INCY? BioMarin Pharmaceutical has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. SummaryIncyte beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?Neurocrine Biosciences (NASDAQ:NBIX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do analysts rate NBIX or BMRN? Neurocrine Biosciences presently has a consensus target price of $184.15, indicating a potential upside of 17.44%. BioMarin Pharmaceutical has a consensus target price of $88.88, indicating a potential upside of 64.20%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 2.82BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75 Which has higher valuation and earnings, NBIX or BMRN? Neurocrine Biosciences has higher earnings, but lower revenue than BioMarin Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.86B5.51$478.60M$6.4924.16BioMarin Pharmaceutical$3.22B3.25$348.90M$1.3739.51 Does the media prefer NBIX or BMRN? In the previous week, BioMarin Pharmaceutical had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 15 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.43 beat BioMarin Pharmaceutical's score of 0.13 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of NBIX or BMRN? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, NBIX or BMRN? Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Is NBIX or BMRN more profitable? Neurocrine Biosciences has a net margin of 21.55% compared to BioMarin Pharmaceutical's net margin of 8.29%. Neurocrine Biosciences' return on equity of 19.79% beat BioMarin Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% BioMarin Pharmaceutical 8.29%6.50%5.07% SummaryNeurocrine Biosciences beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition ExportMetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.44B$3.35B$6.33B$12.33BDividend YieldN/A2.32%2.80%5.36%P/E Ratio39.4118.8920.8825.51Price / Sales3.25279.14520.5073.06Price / Cash17.46125.3543.1855.00Price / Book1.686.9010.017.03Net Income$348.90M$24.18M$3.54B$334.92M7 Day Performance1.66%0.77%0.38%-0.40%1 Month Performance-0.90%-0.38%-0.02%1.07%1 Year Performance-7.45%63.37%35.07%34.65% BioMarin Pharmaceutical Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.4963 of 5 stars$53.77+7.1%$88.88+65.3%-16.2%$10.39B$3.22B39.263,221Analyst ForecastGap UpALNYAlnylam Pharmaceuticals4.672 of 5 stars$291.01-0.8%$471.96+62.2%+2.3%$38.79B$3.71B79.382,770News CoveragePositive NewsAnalyst UpgradeBIIBBiogen4.1398 of 5 stars$191.47+0.1%$215.62+12.6%+43.9%$28.28B$9.89B20.557,500UTHRUnited Therapeutics3.8941 of 5 stars$567.82-1.4%$619.42+9.1%+82.2%$24.07B$3.18B20.931,400Analyst ForecastInsider TradeAnalyst RevisionINCYIncyte4.6258 of 5 stars$95.59-2.1%$104.26+9.1%+48.7%$19.07B$5.14B13.482,844Analyst Forecast Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors MDGL Competitors IONS Competitors HALO Competitors ALKS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
